-
RNA Therapies Hold The Power To Transform Treatment For Numerous Ailments, But Delivering These Remains Problematic – Will This Biotech Change That?
Tuesday, September 19, 2023 - 7:20am | 251Read More...Thomas Meyer, CEO of Altamira Therapeutics (NASDAQ: CYTO), was recently a guest on Benzinga’s All-Access. Altamira develops RNA-based therapeutics for extrahepatic targets. The company also has legacy programs in allergy and viral infections and inner ear disorders, which it intends to...
